Savara Cash Flow Statement
NASDAQ: SVRAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
4.92+0.09 (+1.86%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Savara free cash flow
In fiscal 2025, Savara generated -$101.0 million of operating cash flow and spent $22,000 on capital expenditures. That left free cash flow of -$101.1 million.
Summary generated from market data by MetaCap's automated system. Methodology
Savara cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -118.84M | -95.88M | -54.70M | -38.15M | -43.01M | -49.62M | -78.17M | -61.52M | -29.80M | -10.92M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 87.00K | 130.00K | 77.00K | 31.00K | 136.00K | 255.00K | 1.01M | 526.00K | 363.00K | 99.00K |
| Stock-Based Compensation | 14.42M | 9.86M | 4.18M | 2.04M | 3.26M | 5.11M | 4.44M | 3.74M | 552.00K | 209.00K |
| Change in Working Capital | 97.00K | -2.38M | -456.00K | 1.34M | -1.04M | -134.00K | 148.00K | 900.00K | -2.40M | -9.25M |
| Operating Cash Flow | -101.04M | -89.09M | -51.06M | -34.55M | -40.08M | -39.84M | -45.12M | -39.27M | -28.23M | -8.37M |
| Capital Expenditures | -22.00K | -25.00K | -296.00K | -9.00K | -57.00K | -47.00K | -148.00K | -141.00K | -495.00K | -8.00K |
| Investing Cash Flow | -18.44M | -39.94M | -57.12M | 52.65M | -69.46M | 9.05M | 15.74M | -13.62M | -69.11M | -8.00K |
| Debt Issued | 29.60M | — | — | 26.44M | — | — | — | — | — | — |
| Debt Repaid | -27.23M | — | — | -26.35M | — | -514.00K | — | — | -3.57M | — |
| Financing Cash Flow | 137.81M | 117.58M | 82.78M | 87.00K | 120.81M | 3.69M | 54.91M | 55.19M | 106.09M | 5.12M |
| Net Change in Cash | 18.05M | -11.46M | -25.52M | 18.09M | 11.13M | -26.92M | 25.50M | 2.18M | 8.75M | -3.31M |
| Free Cash Flow | -101.06M | -89.11M | -51.36M | -34.56M | -40.14M | -39.88M | -45.27M | -39.42M | -28.73M | -8.38M |
This table shows 10 annual periods of Savara's cash flow statement, from FY 2025 back to FY 2016, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow SVRA's reporting calendar. What is a cash flow statement?